Dor Aktie - DOR

Dor Biopharma (DOR) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

( - )

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today the first successful evaluation in animal tests of a nasal, bivalent...

DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors

DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR) announced that it has entered into definitive agreements for the sale of securities in a...

DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec

DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company") announced today its financial results for 2005. ? Revenues for 2005 were $3,075,736...

DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that it is focusing its resources on the preparation of New Drug...

DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced results of a Phase I clinical trial of RiVax(TM), a recombinant vaccine...

DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced that it has successfully completed the second development milestone for...

DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that as part of its process to submit a New Drug Application ("NDA") for...

DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital

DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR), today announced that it has entered into a common stock purchase agreement with Fusion...

DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec

DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company"), announced today that following written communications and meetings with the FDA and with...

DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N

DOR BioPharma Inc. (AMEX: DOR) ("DOR" or the "company") announced today its financial results for the third quarter ended Sept. 30, 2005. The...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

DOR - Frequently Asked Questions (FAQ)

What is the current Dor Biopharma share price?

The current share price of Dor Biopharma is US$ 0,00

What is the 1 year trading range for Dor Biopharma share price?

Dor Biopharma has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Dor Biopharma (DOR)

Dor Biopharma (DOR) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

DOR Neueste Nachrichten

DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression

DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors

DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec

DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)

DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well

DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea

DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res

DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital

DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec

DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N

DOR - Frequently Asked Questions (FAQ)

DOR Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Dor Biopharma (DOR)

Dor Biopharma (DOR) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

DOR Neueste Nachrichten

DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression

DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors

DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec

DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)

DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well

DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea

DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res

DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital

DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec

DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N

DOR - Frequently Asked Questions (FAQ)

DOR Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE